Loading...
Please wait, while we are loading the content...
Similar Documents
3 , 4-diaminopyridine Phosphate in the Treatment of Lambert – Eaton Myasthenic Syndrome
| Content Provider | Semantic Scholar |
|---|---|
| Author | Ieb, Jörn Peter S. |
| Copyright Year | 2012 |
| Abstract | 3,4-diaminopyridine (3,4-DAP, amifampridine) is the leading treatment for Lambert–Eaton myasthenic syndrome (LEMS), an autoimmune disorder with impaired neuromuscular transmission, for which few effective medications are currently available. 3,4-DAP has been available as a therapy for LEMS in special treatment programmes for approximately 25 years. As an unlicensed drug, doses for oral administration are required to be compounded by local, hospital or other compounding pharmacies from the base chemical. Administering the correct dose of 3,4-DAP is critical; overdosing can increase the risk of seizures and other adverse events, while underdosing can result in a substantial loss of efficacy or even treatment failure. Two recent studies, have shown a wide variation in the 3,4-DAP content of compounded preparations (22.2–125.2 %, n=9) and (53.5–128.5 %, n=21), thereby reflecting the possibility of patients receiving dosages that might be above safety limits or even markedly below efficacy limits. This inconsistency results from the variable quality and instability of the base chemical and compounding errors. A formulation of 3,4-DAP phosphate salt has now been licensed in Europe and the US with orphan medicinal product status and appears to be as efficacious as the base in relieving the symptoms of LEMS. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.touchneurology.com/system/files/private/articles/10286/pdf/sieb.pdf |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | 3,4-diaminopyridine Administration, Oral Adverse event Autoimmune Diseases Carbamoyl-Phosphate Synthase I Deficiency Disease Dosage Instability Lambert Myasthenic Syndrome Neuromuscular Diseases Not invented here Patients Pharmaceutical Preparations Seizures Wolff-Parkinson-White Syndrome neuromuscular transmission |
| Content Type | Text |
| Resource Type | Article |
